
Product Performance and Advisories
Neuromodulation
Medtronic uses a prospective, long-term multi-center registry to monitor the performance of certain neuromodulation products at selected centers. This 2023 product performance report provides data on the devices followed in the registry. Medtronic also incorporates the findings of returned product analysis (RPA) for devices followed in the registry that are returned to Medtronic.
Depending upon geography, this report may contain information outside approved labeling for commercially available devices from Medtronic. It is recognized that healthcare providers prescribe approved therapies to meet specific patient needs; however, Medtronic only directs the use of its products according to geography-specific, approved labeling.